2019 American Society of Clinical Oncology Annual Meeting*

Download All
May 31 - June 4, 2019; Chicago, Illinois
Review slidesets and analyses of key data from the 2019 Oncology meeting.

Hematologic Malignancies

Capsule Summary Slidesets

In patients with R/R CLL previously treated with ibrutinib, use of the CD19-directed CAR T-cell therapy lisocabtagene maraleucel was associated a high response rate and undetectable MRD along with low rates of grade ≥ 3 CRS and neurologic events.

Released: June 7, 2019

Venetoclax/obinutuzumab produced significantly longer PFS and higher MRD negativity rates compared with chlorambucil/obinutuzumab in patients with previously untreated CLL and comorbidities.

Released: June 10, 2019

Umbralisib monotherapy demonstrated clinical activity in patients with relapsed/refractory marginal zone lymphoma previously treated with CD20-directed therapy.

Released: June 7, 2019

In patients with non-GCB DLBCL, the use of RLI followed by RLI plus chemotherapy produced high response rates and prolonged survival times that compared favorably with historical results.

Released: June 11, 2019

Lenalidomide significantly decreased the risk of progression vs observation in patients with high-risk smoldering multiple myeloma.

Released: June 5, 2019

Including ASCT after KRd induction therapy leads to higher persistent MRD negativity rate and reduces risk of early relapse in NDMM.

Released: June 3, 2019

Iberdomide, a novel IMiD, was well tolerated and active in heavily pretreated patients with R/R MM.

Released: June 7, 2019

The BiTE construct AMG 420 induces rapid clinical responses, including MRD negativity, in patients with relapsed/refractory multiple myeloma.

Released: June 4, 2019
Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Amgen
Celgene Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue